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Pregnancy
Inhibition of Trophoblast-Induced Spiral Artery Remodeling
Reduces Placental Perfusion in Rat Pregnancy
Stefan Verlohren, Nele Geusens, Jude Morton, Iris Verhaegen, Lydia Hering, Florian Herse,
Joachim W. Dudenhausen, Dominik N. Muller, Friedrich C. Luft, Judith E. Cartwright,
Sandra T. Davidge, Robert Pijnenborg, Ralf Dechend
Abstract—Rats harboring the human angiotensinogen and human renin genes develop preeclamptic features in pregnancy.
The preeclamptic rats exhibit a deeper trophoblast invasion associated with a reduced resistance index by uterine
Doppler. Doxycycline inhibits matrix metalloproteinase activity. We tested the hypothesis that matrix metalloproteinase
inhibition reduces trophoblast invasion with subsequent changes in placental perfusion. Preeclamptic and pregnant
control Sprague-Dawley rats were treated with doxycycline (30 mg/kg of body weight orally) from gestational day 12
until day 18. Placental perfusion was assessed using a micromarker contrast agent. The animals were euthanized on day
18 of pregnancy; biometric data were acquired, and trophoblast invasion was analyzed. Doxycycline resulted in
intrauterine growth retardation and lighter placentas in both groups. Maternal body weight was not affected. As shown
earlier, preeclamptic rats exhibited a deeper endovascular trophoblast invasion. However, doxycycline treatment
reduced trophoblast invasion in the preeclamptic rats. The physiological spiral artery remodeling, as assessed by the
deposition of fibrinoid and -actin in the spiral artery contour, was significantly reduced by doxycycline. The vascularity
index, as assessed by perfusion measurement of the placenta, was reduced after doxycycline treatment in preeclamptic rats.
Thus, matrix metalloproteinase inhibition with doxycycline leads to reduced trophoblast invasion and associated reduced
placental perfusion. These studies are the first to show that reducing trophoblast-induced vascular remodeling decreases
subsequent placental perfusion. Our model allows the study of dysregulated trophoblast invasion and vascular remodeling in
vivo to gain important insights into preeclampsia-related mechanisms. (Hypertension. 2010;56:304-310.)
Key Words: pregnancy  trophoblast  rats  animal models  doxycycline
 matrix metalloproteinases  preeclampsia
Preeclampsia (PE) affects 3% to 5% of all pregnancies andis a major cause of fetal and maternal morbidity and
mortality.1 Malimplantation of the placenta leads to hyperten-
sion, proteinuria, and endothelial dysfunction after 20 weeks’
gestation.2,3 In early onset PE, the endovascular and interstitial
trophoblast invasions are reduced, leading to incomplete
placental bed spiral artery remodeling, resulting in reduced
oxygen and nutrients to the fetus.4 Uterine blood flow is
altered, reflecting the failure of trophoblasts to transform the
placenta into low-resistance vessels.5 Trophoblast invasion
and its regulation are poorly understood, and animal models
are problematic. Male rats transgenic for human renin mated
with dams transgenic for the human angiotensinogen develop
hypertension, proteinuria, and fetal loss in the second half of
pregnancy.6,7 However, in contrast to humans, trophoblast
invasion in the rat mesometrial triangle (MT) is deeper rather
than shallow, as in humans.8 The uterine resistance index is
reduced in the PE-model rats; however, the uterine arteries
exhibit endothelial dysfunction.9 Although human PE differs
substantially from this PE rat model, there is homology regard-
ing trophoblast invasion and parallels in important regulatory
elements.10 Studies suggest that trophoblast invasion is regulated
by the interaction of autocrine factors from the trophoblasts and
paracrine factors from the uterus. Trophoblast invasion, like
tumor invasion, is attributed to the active production of proteo-
lytic enzymes to digest extracellular matrices of the host’s
tissues. The secretion of matrix metalloproteinases (MMP) is a
key event. MMPs have been localized in the placental bed,11
trophoblast,12 and uterine natural killer (uNK) cells.13 Although
our rat model is imperfect, we elected to investigate MMPs in
the process of trophoblast invasion because invasion is aberrant
both in human PE and in our animal model, because MMPs
could be pivotal to PE.
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Materials and Methods
Local authorities approved the studies that met American Physiolog-
ical Society guidelines. Details on the transgenic rat model are
published.6 Systolic blood pressure was measured in awake animals
by the tail-cuff method before and after the treatment period.7
Pregnancy was confirmed by inspecting the vaginal plug after
overnight breeding, counted as gestational day 1 of pregnancy.
Sprague-Dawley females were mated with Sprague-Dawley males as
a control group. PE and pregnant control rats were treated with
doxycycline hyclate (DOX; 30 mg/kg of body weight per oral gavage
per day) for 7 days from gestational day 12 until day 18. This dose
inhibits MMP activity.14,15 DOX was prepared in 4% carboxy-
methyl cellulose and applied in light-shielded bottles. On day 18 of
rat pregnancy, measurement of placental perfusion via ultrasound
was performed. Placental perfusion was assessed using contrast
agent microbubbles (VisualSonics). After ultrasound examination,
all of the animals were euthanized, and organs were harvested,
weighed, and analyzed. The MT was separated from the placenta
after weighing and either snap frozen in liquid nitrogen or dehy-
drated in paraformaldehyde or zinc fixative. Analysis of the depth of
trophoblast invasion was performed as described earlier.8 MMP
inhibition by DOX was assessed using RT-PCR, Western blotting,
gel zymography, ELISA, and activity measurement via fluorogenic
peptides. For statistics, we present all of the values as meanSEM.
Student t tests or ANOVA was used as appropriate. A value of
P0.05 was considered statistically significant. Further methodolog-
ical details are given in the online Data Supplement (available at
http://hyper.ahajournals.org).
Results
The PE rat systolic blood pressure was 1657 mm Hg, whereas
blood pressure was 1104 mm Hg in the control group. DOX
treatment had no effect on blood pressure (PEDOX:
1619 mm Hg; controlDOX: 1074 mm Hg). Treatment of
isolated human trophoblasts with 15 mol/L of DOX caused
reduced (P0.05) invasion by 40% (Figure 1). Epidermal
growth factor (EGF), a well-known stimulus of trophoblast
invasion, increased trophoblast invasion. Adding DOX to EGF
resulted in a significant decrease in invasion. Angiotensin (Ang)
II (106 M) also augmented trophoblast invasion, similar to the
observed effect with EGF. DOX also reduced the invasion of
trophoblasts to untreated controls. We next investigated the in
vivo effects of DOX in our transgenic Ang II–dependent PE rat
model. DOX 30 mg/kg per day from gestational day 11 to day
18 did not harm the overall ability of the rats to maintain
pregnancy. The litter size, as well as the resorption number, did
not differ in DOX-treated animals compared with controls.
However, DOX resulted in mild intrauterine growth retardation
in PE (12% reduced body weight). In control animals, DOX
reduced body weight by 8.5% (P0.05). The placentas were
also 10.5% lighter in PE and 12.5% in controls (P0.05).
Maternal body weight was not affected by the DOX treatment
(please see Figure S1 in the online Data Supplement, available at
http://hyper.ahajournals.org). DOX treatment did not result in
liver and renal dysfunction, measured as liver enzymes, creati-
nine, and urea (data not shown). DOX also had no influence on
the nonpregnant female control and human angiotensinogen rats
(data not shown).
DOX treatment inhibited endovascular trophoblast inva-
sion in the MT of the rat placental bed (Figure 2A and 2B).
We focused on physiological remodeling of the spiral arteries
in response to trophoblast invasion. We analyzed spiral artery
segments in 3 depth levels of the MT, the inner compartment
1, the middle compartment 2, and the outer compartment 3
(Figure 2A and 2B). In compartment 2, the spiral artery
remodeling was reduced in PE and controls after DOX
treatment. There was significantly less fibrinoid deposition, and
more -actin–positive cells were present in the spiral artery wall,
indicating less trophoblast-induced remodeling (Figure 2Ci and
2Di). In the outer depth level (compartment 3), DOX reduced
spiral artery remodeling as assessed by the deposition of fibrin-
oid (Figure 2Cii and 2Dii). However, -actin in the spiral
arteries was reduced in the control animals (Figure 2C and 2D).
The physiological spiral artery remodeling, as assessed by the
deposition of fibrinoid and -actin in the spiral arteries of the
overall MT, was also significantly reduced in PE animals by
DOX treatment (data not shown).
The role of apoptosis and uNK cells in DOX-mediated
reduction in trophoblast invasion was examined. In the
untreated animals, a similar number of perivascular Dolichus
biflorus agglutin–positive uNK cells per centimeter squared
was found concerning the spiral artery cross-sections from
the whole MTs in all of the groups. In the DOX-treated PE
rats and in control animals, a significantly enhanced apoptosis
was exhibited (Figure 3A; P0.05). We next evaluated the
uNK cell content in the MT. There were significantly more
uNK cells in the MT of the PEDOX as compared with the
controlDOX (Figure 3B; P0.05).
The vascularity index, as assessed by perfusion measure-
ment of the placenta, was reduced (P0.05) after DOX
treatment in PE rats (Figure 4A through 4D). The area under
the curve of perfusion of the maternal arterial channel as
assessed in the sagittal ultrasound scan was significantly
reduced in the DOX-treated animals. However, in controls
there was no significant change in perfusion. In the transver-
sal scan of the placenta, DOX treatment significantly reduced
the resistance index in the PE rats. In the transversal plane,
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Figure 1. Isolated human trophoblasts (SGHPL-4) were incu-
bated with Ang II, DOX, and EGF. Cells were cultured on micro-
carrier beads embedded in fibrin gels to assess invasion. Incu-
bation with DOX significantly decreased the motility of the cells
in vitro. Ang II and EGF increased invasion of the trophoblasts.
This effect was antagonized by DOX (n4 experiments each
with 20 beads per group; *P0.05). The y axis represents the
length of invasive processes (AU indicates arbitrary units).
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significant differences in the vascularity index of the un-
treated controls versus PE animals were observed. The
untreated control animals exhibited a significantly reduced
area under the curve of micromarker perfusion as compared
with the untreated PE animals (P0.05).
Quantitative RT-PCR showed that MMP-2 was increased in
the MT of PEDOX compared with controlDOX (Figure
5A). The results were confirmed by Western blot and ELISA
(Figure 5B and 5C), showing a highly preserved MMP2 expres-
sion in the PE rats after DOX treatment, which verifies the
positive feed back loop after downstream inhibition by DOX.
Because DOX is not present in the organ extract after extraction,
the preserved MMP-2 expression was enzymatically active
(Figure 5D and 5E). Add back of DOX (35 mol/L) was
successful in inhibiting MMP activity (Figure 5F). This proof-
of-concept effect was present in the MT, as well as in the
placenta (data not shown). Adding back DOX was successful in
control tissue and DOX-treated organs (data not shown).
Discussion
The data indicate a causal relationship among reduced tro-
phoblast invasion, reduced spiral artery remodeling, and
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Figure 2. DOX treatment resulted in a decreased trophoblast invasion as reflected by a decreased physiological remodeling of spiral
arteries. A representative placental section is shown in A (cytokeratin staining for trophoblasts). The yellow lines represent the depth
levels of the MT that were used to analyze the depth of spiral artery invasion by trophoblasts. In B, a representative section of the MT
is displayed. C shows a representative Periodic acid-Schiff staining of an MT spiral artery. DOX-treated animals show a significantly
lower percentage of fibrinoid staining of the spiral artery contour in compartment 2 (Ci), indicating less physiological and less deep tro-
phoblast invasion (Ci, n6; *P0.05). Analogous effects are visible in the outer depth level (compartment 3) of the MT. There was
almost no fibrinoid deposition as a marker of physiological remodeling visible in the controls, whereas there is a significant reduction of
trophoblast invasion in the DOX-treated PE animals (Cii, n6; *P0.05). D shows a representative -actin–stained section of an MT
spiral artery. DOX-treated animals show a higher percentage of -actin staining of the spiral artery contour staining in compartment 2
(Di) and compartment 3 (Dii), indicating less physiological change in the MT (n6; *P0.05).
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subsequent reduction of placental perfusion in a transgenic
PE rat model. MMP inhibition with DOX led to reduced
trophoblast invasion in the PE group. The physiological
remodeling of the spiral arteries in the outer depth level of the
MT was reduced by 60%. The novel and accurate method of
microbubble-assisted, contrast-enhanced ultrasonography
perfusion of the placenta demonstrated that DOX treatment
reduced perfusion by 25%. We were able to show inhibition
of trophoblast invasion by DOX in vitro by studying tropho-
blasts from first-trimester human pregnancies. Furthermore,
we were able to explain a part of the initially puzzling
observation in our PE rats. These rats express a deeper
trophoblast invasion compared with controls, which is oppo-
site to the human situation.8 In the cell culture system,
supplementing Ang II with the medium led to an increased
invasion of cultured trophoblast cells in vitro. When adding
DOX, this effect was blocked. When a known stimulator of
trophoblast invasion (EGF) was substituted in vitro, invasion
also occurred that could be blocked by DOX.16
Invasion of trophoblast into the decidua and myometrium,
as well as the remodeling of the spiral arteries, is an important
feature of hemochorial placentation.1 Uterine spiral arteries
are vital to supply oxygen and nutrients to the placenta and
fetus. The main purpose of trophoblast-induced spiral artery
remodeling is to transform the artery into a highly dilated
vessel. Although the important role of trophoblasts in the
complete physiological change of the spiral arteries is ac-
cepted, uncertainties about the molecular pathways and
mechanisms of spiral artery remodeling remain. Our knowl-
edge is mainly based on meticulous histological observations.
Few data have been generated by ex vivo experimental
systems, such as isolated placental bed blood vessels or in
vitro models using explanted spiral artery segments.17,18
Rodent placentation has not been studied in detail. Calu-
waerts et al10 described that changes in spiral arteries of
pregnant rats reveal striking similarities with physiological
changes seen in human pregnancy. Our study is a follow-up
of that pioneering work. We inhibited trophoblast invasion
with DOX and demonstrated that placental perfusion is
causally connected with trophoblast invasion.
In human and rodent pregnancies, uNK cells control
trophoblast invasion.19,20 Trophoblast invasion follows the
demise of uNK cells and is directed toward regions of the
MT, which were occupied previously by uNK cells. In our
study, apoptosis is increased after DOX treatment in PE and
control rats (Figure 3A). We were able to show that the
presence of uNK cells is significantly increased after DOX
treatment only in PE and not in control rats (Figure 3B).
Increased apoptosis of perivascular uNK cells might offer an
explanation for the increased endovascular trophoblast inva-
sion. DOX treatment leads to a reduction in endovascular
trophoblast invasion by a reduction of uNK-cell apoptosis
and a preservation of uNK cells in the MT.
Factors controlling endovascular invasion are still poorly
understood. There is clear agreement that trophoblast invasion is
not attributed to passive growth pressure but instead is an active
biochemical, multistep process involving attachment, degrada-
tion, and migration through extracellular matrix proteins.5,21
MMPs are key proteins in this process.11,13 MMP levels are
elevated in women who subsequently develop PE.22 This inva-
sive behavior is clearly attributed to the ability of cytotropho-
blasts to secrete MMP, because tissue inhibitors of MMP
expression inhibit their invasiveness. The expression of MMP-2
and MMP-9 has been shown to mediate cytotrophoblast inva-
sion into Matrigel. Cytotrophoblast production and activation of
MMP-9 peak during the first trimester of pregnancy, coinciding
with maximal invasive behavior in vivo.11,13 Our data under-
score the importance of MMP. In our model, inhibition of MMP
is sufficient to alter the status of associated vascular remodeling
and might, thus, contribute to alterations in PE.
Our transgenic PE rat model is Ang II driven with high
circulating and uteroplacental Ang II levels.6 Ang II enhances
MMP2 release and might, thus, contribute to the observed
deeper trophoblast invasion and associated changes of flow in
the transgenic rats.23 Chronic administration of Ang II has
been shown to increase MMP expression and subsequently to
induce spiral artery remodeling in rats.24 Inhibition of exag-
gerated MMP2 release could, therefore, contribute to reduced
trophoblast invasion as observed in our intervention. In
earlier studies, several authors have shown a different effect
of the renin-Ang system on uterine blood flow in comparison
with other organs.25,26 Franklin et al27 showed that Ang II
increased uterine artery blood flow via prostaglandins. Li
et al28 were the first to show that endocrine active decidual
cells express both renin and angiotensinogen. They suggested
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Figure 3. The role of apoptosis and uNK cells in DOX-mediated
reduction in trophoblast invasion was examined. A shows a signifi-
cant proapoptotic effect of DOX in PE and controls (staining for
cleaved caspase 3, n6; *P0.05) In B, uNK cells in the MT are
visualized by staining for Dolichus biflorus agglutin lectin (n6;
*P0.05). There were significantly more DBA cells in the PEDOX
group. No significant changes were provoked in control (C)DOX.
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that decidual cells regulate an expression of a tissue renin-
Ang system in the endometrium. Ferris et al26 also showed
that uterine renin is inducing an increasing uterine blood
flow. Renin secretion is increased in response to a reduction
in uterine blood flow leading to an increase in circulating or
local Ang II. Furthermore, Ang-converting enzyme inhibitors
have also been shown to decrease uterine blood flow, which,
together with fetopathy, is the reason why Ang-converting
enzyme inhibitors should not be used to treat hypertension
during pregnancy.29 DeLano and Schmid-Schonbein30 have
shown that DOX treatment for 24 weeks reduced blood
pressure and protease activity in plasma and microvessels in
spontaneous hypertensive rats. Castro et al31 showed a similar
reduction in hypertension by DOX in a 2-kidney, 1-clip
model for hypertension after 8 weeks of treatment. Thus, we
cannot exclude that the differences in placental perfusion
between control and PE rats by DOX are at least partially
mediated by differences in the uteroplacental or circulating
differences in the renin-angiotensin system.
DOX effectively inhibits MMP activity.32 MMPs are regu-
lated at several levels. Although the expression of most MMPs
is transcriptionally regulated, additional modulation exists at the
level of activation through the secreted latent proenzyme. The
activity of the resultant protease can be inhibited by several
endogenous inhibitors, of which tissue MMP inhibitors appear
most important.33 In addition to signaling pathways, DOX is
believed to act via both primary direct and secondary indirect
mechanisms on MMP activity and cell proliferation.32 The
potential explanations are that DOX nonselectively directly
inhibits MMPs by binding to the active zinc sites and also by
binding to an inactive calcium site, which causes conformational
change and loss of enzymatic activity.32 Secondary mechanisms
of inhibition have also been proposed, which include a reduction
in activation,34 decreased gene expression,35 and stabilization of
specific and nonspecific inhibition.32 However, the inhibition of
the active zinc sites is reversible. After the organs were pro-
cessed, DOX was no longer present in the cellular extract. Thus,
detection MMP inhibition by DOX in the target organ via
standard procedures has been difficult. Villarreal et al36 avoided
this problem. They showed that more MMP2 and MMP9
activity was present in the DOX-treated organ in their study.
They described a feedback mechanism involving downstream
MMP inhibition by DOX. In our study, we could show that
MMP2 mRNA and protein expression was increased in the
DOX-treated uteroplacental unit. Global MMP activity was
higher in PE MTs compared with controls. Because DOX is no
longer present in the processed organs, the increased activity,
analogous to the protein expression, is an indirect sign that DOX
was successful during the treatment period. MMP activity was
higher in the formerly DOX-treated organs. We performed an
add-back of DOX (35 mol/L) to the fluorogenic peptide assay.
Adding DOX was successful in inhibiting MMP activity, prov-
ing the concept of the efficacy of the intervention.
We were faced with the obstacle that sharply reduced tropho-
blast invasion might have perturbed the pregnancies before they
could be completed. The teratogenic risk of DOX is well known.
Previous studies by Siddiqui and Janjua37 showed that DOX
administration to pregnant rats is feasible; however, they ob-
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served that the skeletal differentiation in the long bones was
delayed in the fetuses, when pregnant dams were given DOX.
The daily oral DOX dose for effective MMP inhibition in rats
ranges between 25 and 100 mg/kg,34,38 which is substantially
higher than the therapeutic doses given to humans (2 to 3
mg/kg). We observed a moderate disturbance of the pregnancies
in rats given DOX. DOX reduced fetal weight by 8.5% in
control and 11.5% in transgenic PE animals. Placental weight
was diminished by 12.5% in nontransgenic and 10.5% in
transgenic animals, whereas maternal weight was unaffected.
The dose of DOX that we used represents a compromise
between a detectable trophoblast inhibition and a pregnancy
directly perturbed by DOX.
DOX had no significant effect on placental perfusion in the
control rats. Because the presence of trophoblast invasion in
the deep region of the MT is a major determinant, and control
rats show only minor deep trophoblast invasion,8 conceivably
DOX was not successful for this purpose. Nevertheless, we
could show that DOX had strong effects in the control group,
such as intrauterine growth restriction, apoptosis, and vascu-
lar remodeling in the more superficial regions of the utero-
placental unit. Another reason for the different potency of
DOX in the 2 groups might be the known interaction among
hypertension, Ang II, and the MMP system. Hypertension
itself and Ang II increase MMP expression and activity in the
myocardium and in the vasculature. In PE rats, deeper
trophoblast invasion resulted not only in an increased perfu-
sion but also in a dysregulated trophoblast decidua interac-
tion, leading to increased decidual apoptosis and arteriolo-
sclerosis.7 In this respect, the DOX effect may be regarded as
having “normalized” the dysregulated trophoblast invasion.
Perspectives
Trophoblast invasion and spiral artery remodeling in the rat
placenta can be investigated in rat models, including PE
models. Furthermore, MMP inhibition has a distinct effect on
trophoblast invasion in such models. Animal models have
thus far been imperfect in terms of duplicating events
occurring in PE in our model and in other model systems.
However, although rat and human placentas differ substan-
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Figure 5. PCR, Western blot, ELISA, zymography, and MMP-2 activity measurements were performed to assess MMP-2 inhibition by
DOX in the MT. PCR analysis showed a significant upregulation of MMP expression in DOX-treated controls and PE rats (A, n4;
*P0.05). Western blot analysis showed a highly preserved MMP2 protein expression in the PE rats after DOX treatment, verifying a
positive feed back loop after downstream inhibition by DOX (B, n4; P0.05). Protein content was not significantly different after DOX
intervention in the MT of both groups (C, n4; P0.05). MMP activity was not significantly different as assessed by gel zymography in
the MT after DOX intervention in both groups (D, n4; P0.05). The measurement of MMP2 activity with fluorogenic peptides showed
a significantly preserved MMP2 activity after DOX treatment in both groups (E, n4; *P0.05). To verify the inhibition of MMP2 activity
after DOX treatment, add-back of DOX was performed, and activity was measured using the fluorogenic substrates (F, n5; *P0.05).
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tially, the imaging, pathological, and pharmacological tools
that we described here will be applicable to better models that
will be developed in the future.
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Supplementary  Method Section 
 
Placental Perfusion Measurements 
 On day 18 of rat pregnancy, measurement of placental perfusion via ultrasound was 
performed. The rats were anesthetized with isoflurane. Heart rates and temperatures were 
monitored (Model THM100, Indus Instruments) and heating was adjusted to maintain a body 
temperature between 36 and 38°C. All hair was removed from the abdomen by gentle 
shaving. Pre-warmed gel was applied to the abdomen as an ultrasound-coupling medium 
(Parker Laboratory). Rat placentas and mesometrial triangles (MT) were imaged 
transcutaneously using the ultrasound biomicroscope (UBM) and a 30 MHz or 40 MHz 
transducer operating at 30 frames/s (Model Vevo 660, VisualSonics Inc). Placental perfusion 
was assessed using micromarker contrast agent (microbubbles, VisualSonics). Analysis of the 
“wash-in” curves was performed in comparing changes in the slope and plateau and implied 
differences in blood volume and blood flow in normal pregnant and DOX-treated animals. 
The microbubbles were administered intravenously as a continuous infusion at a constant rate 
and concentration. The appearance of the microbubbles in the ultrasound beam represented 
the wash-in by the placental circulation. After steady state of the plateau phase was achieved, 
the microbubbles were washed out of placental circulation. This plateau phase reflected the 
effective microbubble concentration within the placental circulation. The area under the curve 
(AUC) of the wash-in and plateau of the non-targeted micromarkers were used to describe the 
vascularity index (VI). Quantification was performed in adapting the concept of quantification 
of myocardial blood flow with microbubbles as described by Wei et al for the placental bed.1 
Two regions of interest were chosen and contrast agent wash-in and steady state curves were 
evaluated. In the first set of experiments, the region of interest was the maternal arterial 
channel (MAC) in the mesometrial triangle (MT). The blood flow inside the MAC was 
assessed, reflecting the overall remodeling status of the placenta. The MAC was scanned in a 
sagittal plane to visualize the course of the MAC inside the placenta/mesometrial triangle. In 
the second examination, a transversal scan was chosen and fetal side of the placenta was 
assessed. 
Blood analysis 
 Blood was collected in sterile, cold 10-mL tubes and immediately centrifuged at 3000 
rpm for 10 minutes at 4°C for the measurement of serum markers of hepatic (alanine 
aminotransferase [ALAT], aspartate aminotransferase  [ASAT], gamma glutamyl transferase 
[GGT]) and renal function (creatinine and uric acid) in the Charité University Hospital central 
laboratory facility. 
Histology and Immunohistochemistry 
Placentas with their associated mesometrial triangle were paraffin fixed and parallel 
sections were cut step-serially from each implantation site parallel to the mesometrial-fetal 
axis. PAS staining was performed using standard histological protocols to identify a central 
maternal arterial channel (MAC) on one set of parallel sections. Parallel sections from the 
selected set were then stained for cytokeratin as a trophoblast marker, for α-actin as a vascular 
smooth muscle marker, for cleaved caspase-3 as an apoptosis marker and for DBA (Dolichos 
Biflorus Agglutinin) to visualize the uNK cells. The depth of trophoblast invasion was 
assessed using Zeiss KS-400 image analysis system. 2 
MMP-measurements 
RT-PCR was performed as described previously.3 Briefly, two micrograms of total 
RNA were reverse transcribed and analyzed in triplicate with the ABI 5700 sequence 
detection system (PE Biosystems). Primer and probes were designed with PrimerExpress 2.0 
(Applied Biosystems).  
For western blotting, protein from DOX-treated and untretaed placenta and MT were 
processed as described earlier.4 For gelatin zymography, Placentas MT from DOX-treated and 
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untreated rats were extracted with 10 mmol/l Tris _HCl (pH 7.5) extraction buffer. 
Zymography was performed using 7.5% SDS-PAGE with copolymerized gelatin (2 mg/ml) as 
substrate. At the end of each run, gels were washed with 2.5% Triton X-100 and incubated for 
48 h in an enzyme assay buffer (50 mmol/l Tris, pH 7.0, 5 mmol/l CaCl2, 0.15 mol/l NaCl, 
and 0.05% Na3N) to allow for the development of enzyme activity bands. Gels were stained 
with 0.05% Coomassie brilliant blue G-250 in a mixture of methanol: acetic acid: water 
(2.5:1:6.5) and destained in 4% methanol with 8% acetic acid. The gelatinolytic activity was 
detected as transparent bands against the background of Coomassie brilliant blue-stained 
gelatin. Gels were scanned using Fluor-S Multi-Imager (Bio-Rad) and analyzed for pro-
MMP-2 and activated MMP-2 (72-and 64-kDa bands, respectively).  
MMP-2 protein content was measured using commercially available ELISA kits and 
were performed according to the manufacturer’s instructions (R&D Systems). Global MMP-2 
activity was measured by the substrate: MCA-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 (Biomol). 
Fluorescence was kinetically assessed using a microplate reader (340 excitation and 405 
emission). 
 
Cell culture measurements  
A trophoblast invasion assay was used in which SGHPL-4 cells were grown on gelatin 
coated cytodex-3 microcarrier beads embedded in fibrin gels.  In brief cells were at a density 
of 500000 cells/ml with 1500 microcarrier beads/ml and incubated for 1h at 37°C. Fibrin gels 
were prepared by dissolving bovine fibrinogen (>95% of protein clottable, Sigma) in PBS at a 
concentration of 2.5mg/ml and 200U/ml aprotinin (Trasylol, Bayer, Germany) was added. 
Cell-coated microcarrier beads were added at a density of 150 beads/ml and clotting was 
induced by the addition of thrombin (0.625U/ml). After clotting the gels were equilibrated 
with culture medium supplemented with 0.5% (v/v) FCS for 1h. The medium was replaced 
with fresh medium (1:1 volume with the gel) and the cells incubated at 37°C in a humidified 
atmosphere of 5% CO2. After 24h, the medium was replaced with medium containing the 
stimulus and/or the inhibitor as indicated. After 48h at least 10 beads from each plate were 
chosen at random and invasion was observed using an Olympus IX 70 phase contrast 
microscope. Images were captured and the number and length of the processes formed were 
determined using Image Pro-Plus software (Media Cybernetics).5 
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Supplementary Figure: 
 
Fig S1. Embryonic weight (a) and placental weight (b) were reduced by treatment with 30 
mg/kg bodyweight DOX per day from gestational day E11 - E18. Embryonic growth was 
reduced by 11.5 % in PE and 8.5 % in C. Placental weight was reduced by 10.5 % in PE and 
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12.5 % in C (n=45, *p<0.05). Maternal bodyweight (c) was not affected by the DOX 
treatment (n=6, n.s.).  
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